Beta-thalassemia

Last updated: July 01, 2022

Beta-thalassemia

Hematological system

Hematological system

Blood histology
Blood components
Erythropoietin
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Plasmodium species (Malaria)
Anemia: Clinical
Microcytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Iron deficiency anemia
Sideroblastic anemia
Lead poisoning
Alpha-thalassemia
Beta-thalassemia
Macrocytic anemia: Pathology review
Megaloblastic anemia
Vitamin B12 deficiency
Folate (Vitamin B9) deficiency
Fanconi anemia
Diamond-Blackfan anemia
Anemia of chronic disease
Sickle cell disease (NORD)
Sickle cell disease: Clinical
Aplastic anemia
Acute intermittent porphyria
Porphyria cutanea tarda
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Autoimmune hemolytic anemia
Hemolytic disease of the newborn
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Hereditary spherocytosis
Platelet disorders: Pathology review
Heparin-induced thrombocytopenia
Thrombotic thrombocytopenic purpura
Hemolytic-uremic syndrome
Glanzmann's thrombasthenia
Bernard-Soulier syndrome
Coagulation disorders: Pathology review
Hemophilia
Vitamin K deficiency
Mixed platelet and coagulation disorders: Pathology review
Disseminated intravascular coagulation
Von Willebrand disease
Thrombosis syndromes (hypercoagulability): Pathology review
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antithrombin III deficiency
Hemochromatosis
Vasculitis: Pathology review
Vasculitis: Clinical
Shock: Pathology review
Antiphospholipid syndrome
Myeloproliferative disorders: Pathology review
Polycythemia vera (NORD)
Essential thrombocythemia (NORD)
Thrombocytopenia: Clinical
Myelofibrosis (NORD)
Langerhans cell histiocytosis
Lymphomas: Pathology review
Hodgkin lymphoma
Non-Hodgkin lymphoma
Lymphoma: Clinical
Leukemias: Pathology review
Acute leukemia
Chronic leukemia
Leukemia: Clinical
Leukemoid reaction
Myelodysplastic syndromes
Plasma cell disorders: Pathology review
Multiple myeloma
Waldenstrom macroglobulinemia
Monoclonal gammopathy of undetermined significance
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment

Transcript

Watch video only

Beta thalassemia is a genetic disorder where there’s a deficiency in production of the β-globin chains of hemoglobin, which is the oxygen-carrying protein in red blood cells - or RBCs for short. Beta thalassemia is most commonly seen in Mediterranean, African and South East Asian populations.

Normally, hemoglobin is made up of four globin chains, each bound to a heme group. There are four major globin chain types - alpha (α), beta (β), gamma (γ), and delta (δ). These four globin chains combine in different ways to give rise to different kinds of hemoglobin. First, there’s hemoglobin F (or HbF), where F stands for fetal hemoglobin, and it’s made up of two α-globin and two γ-globin chains. Hemoglobin A (or HbA), the major adult hemoglobin form, is made up of two α-globin and two β-globin chains. Finally, hemoglobin A2 (or HbA2)) accounts for a small fraction of adult hemoglobin in the blood, and it’s made up of two α-globin and two δ-globin chains. With beta thalassemia, there’s either a partial or complete β-globin chain deficiency, due to a point mutation, which is when a single nucleotide in DNA is replaced by another nucleotide, in the beta globin gene present on chromosome 11. And most often, these mutations occur in two regions of the gene called the promoter sequences and splice sites, which affects the way the mRNA is read. The result is either a reduced, or completely absent beta globin chain synthesis.

And since this is an autosomal recessive disease, two mutated copies of this gene, one from each parent, are needed to develop the disease. If the person has just one mutated gene that codes for either a reduced production or absent production of beta globin chains, then they have beta thalassemia minor. If the person has two mutated genes that code for reduced beta globin chain synthesis, then they’re said to have beta thalassemia intermedia. If the person has two β0 mutations then no beta globin chains are produced, and they’re said to have beta thalassemia major.

When there’s a β-globin chain deficiency, free α-chains accumulate within red blood cells, and they clump together to form intracellular inclusions, which damage the red blood cell’s cell membrane. This causes hemolysis, or red blood cells breakdown in the bone marrow; or extravascular hemolysis, when red blood cells are destroyed by macrophages in the spleen. Hemolysis causes hemoglobin to spill out directly into the plasma, where heme is recycled into iron and unconjugated bilirubin. Over time, the excess unconjugated bilirubin leads to jaundice, and excess iron deposits leads to secondary hemochromatosis.

At the same time, hemolysis leads to hypoxia, because there are fewer red blood cells to carry oxygen to organs and tissues. And a consequence of hypoxia is that it signals the bone marrow, and extramedullary tissues like the liver and spleen, to increase red blood cell production, which may cause bone marrow containing bones, like those in the skull and face, as well as the liver and spleen, to enlarge.

Ok, now, beta thalassemia minor is usually asymptomatic. On the other hand, with beta thalassemia major, symptoms do not develop until the first 3 to 6 months of life. That’s because during the first 3 to 6 months of life, fetal hemoglobin is still produced, and that process uses up some of the free α-chains. Common beta thalassemia major signs and symptoms include symptoms of anemia like pallor, shortness of breath, and easy fatigability; jaundice, swollen abdomen due to an enlarged liver and spleen, hepatosplenomegaly; and growth retardation. Complications due to hemochromatosis include arrhythmias, pericarditis, cirrhosis, hypothyroidism and diabetes mellitus.

Key Takeaways

Thalassemia (British English: thalassaemia), also called Mediterranean anemia, is a form of inherited autosomal recessive blood disorder characterized by abnormal formation of hemoglobin. The abnormal hemoglobin formed results in improper oxygen transport and destruction of red blood cells. Thalassemia is caused by variant or missing genes that affect how the body makes hemoglobin, the protein in red blood cells that carries oxygen. People with thalassemia make less hemoglobin and have fewer circulating red blood cells than normal, which results in mild or severe microcytic anemia.

Sources

  1. "Robbins and Cotran Pathologic Basis of Disease, Professional Edition E-Book" Elsevier Health Sciences (2014)
  2. "Contemporary Internal Medicine" Springer Science & Business Media (2012)
  3. "Molecular Pathology in Clinical Practice" Springer Science & Business Media (2007)
  4. "Guidelines for the Clinical Management of Thalassaemia" NCBI (2007)